HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Desouza, C. Articles by Fonseca, V. A. Search for Related Content PubMed PubMed Citation Articles by Desouza, C. Articles by Fonseca, V. A. Social Bookmarking                What's this?

Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes

From Tulane University Health Sciences Center, New Orleans, Louisiana

OBJECTIVE—Flow-mediated dilatation (FMD), induced by occlusion of the brachial artery, is an index of nitric oxide-dependent endothelial function that is impaired in patients with type 2 diabetes. Sildenafil (Viagra) is an inhibitor of phosphodiesterase 5 (PDE-5), which is used for management of erectile dysfunction in a broad range of patients, including those with type 2 diabetes. Its effects on endothelial function in these patients have not been previously assessed.

RESEARCH DESIGN AND METHODS—We assessed the acute and prolonged effects of a low dose of sildenafil (25 mg) on FMD in patients with type 2 diabetes. We performed a double-blind, placebo-controlled cross-over trial in 16 patients (14 of whom completed the study) with type 2 diabetes who had erectile dysfunction without overt clinical heart disease.

RESULTS—In these patients, the mean ± SD brachial artery diameter (BAD) measured by ultrasound was 4.33 ± 0.6 mm. After inducing FMD, the BAD increased 8% to 4.66 ± 0.6 mm (P = 0.2). One hour after oral administration of sildenafil 25 mg, FMD increased the BAD significantly by 15% to 4.99 ± 0.5 mm (P 0.01), whereas it did not change with placebo (4.6 ± 0.6 mm, P = 0.1). After treatment with sildenafil 25 mg daily for 2 weeks and testing 24 h after the last dose, the mean FMD was 14% (P = 0.01). In contrast, the mean FMD with placebo was 9% (P = 0.45).

CONCLUSIONS—We conclude that acute and prolonged sildenafil treatment has a favorable effect on brachial artery flow-mediated dilatation that persists for at least 24 h after the last dose. Further investigation is needed to determine whether this prolonged effect has clinical implications in patients with type 2 diabetes.

Abbreviations: BAD, brachial artery diameter • cGMP, cyclic guanosine monophosphate • FMD, flow-mediated dilatation • PDE, phosphodiesterase

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. L. Burnett Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health J Androl, January 1, 2008; 29(1): 3 - 14. [Abstract] [Full Text] [PDF]

				M.G. Ferrini, I. Kovanecz, S. Sanchez, D. Vernet, H.H. Davila, J. Rajfer, and N.F. Gonzalez-Cadavid Long-Term Continuous Treatment with Sildenafil Ameliorates Aging-Related Erectile Dysfunction and the Underlying Corporal Fibrosis in the Rat Biol Reprod, May 1, 2007; 76(5): 915 - 923. [Abstract] [Full Text] [PDF]

				R. Fries, K. Shariat, H. von Wilmowsky, and M. Bohm Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy Circulation, November 8, 2005; 112(19): 2980 - 2985. [Abstract] [Full Text] [PDF]

				M. Diomedi, F. Sallustio, B. Rizzato, F. Ferrante, G. Leone, E. Spera, M. Scarfini, and G. Bernardi Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study Neurology, September 27, 2005; 65(6): 919 - 921. [Abstract] [Full Text] [PDF]

				R. Bouley, N. Pastor-Soler, O. Cohen, M. McLaughlin, S. Breton, and D. Brown Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra) Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1103 - F1112. [Abstract] [Full Text] [PDF]

				D. O. Sussman Pharmacokinetics, Pharmacodynamics, and Efficacy of Phosphodiesterase Type 5 Inhibitors J Am Osteopath Assoc, March 1, 2004; 104(3_suppl): 11S - 15S. [Abstract] [Full Text]

				C. Vlachopoulos, K. Hirata, and M. F O'Rourke Effect of sildenafil on arterial stiffness and wave reflection Vascular Medicine, November 1, 2003; 8(4): 243 - 248. [Abstract] [PDF]

				L. Khaodhiar and A. Veves Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes Diabetes Care, March 1, 2003; 26(3): 962 - 963. [Full Text] [PDF]

				V. Fonseca Acute and Prolonged Effects of Sildenafil on Brachial Artery Flow-Mediated Dilatation in Type 2 Diabetes: Response to Khaodhiar and Veves Diabetes Care, March 1, 2003; 26(3): 963 - 963. [Full Text] [PDF]